Organon: Humira A ‘Whole Different Animal’ To Other US Biosimilars
US-Based Firm Also In Discussions To Expand Biosimilar Pipeline
Executive Summary
Shortly after filing for a high-concentration biosimilar adalimumab product with partner Samsung Bioepis, Organon has provided in-depth commentary for its expectations around the impending formation of the market, forecasting a “free for all” six months post-formation.
You may also be interested in...
Generics Bulletin Editor’s Picks For Q1 2022
Looking back over the first quarter of 2022, Generics Bulletin executive editor David Wallace picks out highlights from January to March that include a number of major deals in the biosimilars sector, warnings of increasing price pressure on generics, and key strategy updates from companies across the off-patent sector.
Humira One Year Out: The Largest LOE Event In US Pharma History
Ahead of the first biosimilar Humira product set to launch in less than a year, In Vivo provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.
Humira One Year Out: The Largest LOE Event In US Pharma History
Ahead of the first biosimilar Humira product set to launch in 365 days, Generics Bulletin provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.